FDA Approves Vusolimogene Oderparepvec Plus Nivolumab for PD-1-Refractory Advanced ...

The FDA has approved the combination therapy of Vusolimogene Oderparepvec and Nivolumab to treat PD-1-refractory advanced melanoma, offering a new treatment option for patients who previously had limited responses to PD-1 inhibitors.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.